Admin
... Read More
By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. Cookie Policy.
Written By: Admin | Updated : October 7, 2016 1:00 PM IST
A lot of noise is being made about the Piramal's recent acquisition of Bayer's molecular imaging portfolio but what does it really imply?
According to chairman Mr Ajay Piramal it s a shift from being a maker of branded generic-versions of medicines to creating exclusive patent-protected products. Now this is a distinct shift of ideology for Indian pharma companies considering the recent compulsory licensing case, which allowed Natco to copy and reproduce Bayer s anti-cancer drug at a cut-price rate. Till now companies were happy to replicate the big global players drugs and refused to compete with them for R & D. This acquisition could signify a new dawn for India pharmaceutical companies where they take on the big players at their own game.
This transaction also included the rights to florbetaben. Florbetaben is a PET tracer for the detection of beta-Amyloid plaque deposition in the brain, which is the pathological hallmark of disease in probable Alzheimer s disease patients. Detection of beta-Amyloid depositions is expected to result in earlier diagnosis and more specific treatment of Alzheimer s disease. Whether this will signify a substantial slash in medicine costs even down the line is still unclear. DespiteRoche s recent announcement to sell generic versions of two of its cancer drugsat cut-price rates in India, drugs for chronic diseases, despite compulsory licensing is still too expensive for most people.
Does this acquisition mean that in the near future if there is a breakthrough in Alzheimer s treatment people will be able to afford it? Sadly the answer to that for the time being is no. Watch this space.
